Phase Ii Randomized Trial Of Afatinib With Or Without Cetuximab As First-Line Treatment For Egfr Mutated Non-Small Cell Lung Cancer (Nsclc) Patients (Ifct-1503 Ace-Lung).
JOURNAL OF CLINICAL ONCOLOGY（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要